The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I/II study of MEDI-551, a humanized monoclonal antibody targeting CD19, in subjects with relapsed or refractory advanced B-cell malignancies.
Trishna Goswami
Employment or Leadership Position - MedImmune; MedImmune
Andres Forero
Research Funding - MedImmune
Mehdi Hamadani
Honoraria - Celgene
Anne Sonet
No relevant relationships to disclose
Gregor Verhoef
No relevant relationships to disclose
Michelle A. Fanale
Research Funding - MedImmune
Celeste M. Bello
No relevant relationships to disclose
Wenmei Huang
Employment or Leadership Position - MedImmune
Bruce D. Cheson
No relevant relationships to disclose